Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report

Aisling Barrett; Toby A Eyre; Shaheel Bhuva; Mahmoud Aljurf; Riad El Fakih; Mohammad A Ashshi; Alfadel Alshaibani

doi:10.1002/jha2.830

Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report

EJHaem. 2023 Dec 26;5(1):238-241. doi: 10.1002/jha2.830. eCollection 2024 Feb.

Authors

Aisling Barrett¹, Toby A Eyre¹, Shaheel Bhuva², Mahmoud Aljurf³, Riad El Fakih³, Mohammad A Ashshi⁴, Alfadel Alshaibani³

Affiliations

¹ Department of Clinical Haematology Oxford Cancer and Haematology Centre Oxford University Hospitals NHS Foundation Trust Oxford UK.
² Department of Clinical Radiology Oxford University Hospitals NHS Foundation Trust Oxford UK.
³ Department of Stem Cell Transplant and Cellular Therapy King Faisal Specialist Hospital and Research Center Riyadh Saudi Arabia.
⁴ College of Medicine Umm Al-Qura University Makkah Saudi Arabia.

Abstract

Central nervous system (CNS) involvement by mantle cell lymphoma (MCL) is rare and portends a poor prognosis. We describe the first patient to have a complete response with front-line treatment with single-agent acalabrutinib for MCL CNS.

Keywords: PET in lymphoma; acalabrutinib; case report; central nervous system lymphoma; mantle cell lymphoma.

Publication types

Case Reports